Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Kiklin bixalomer regulatory update

October 10, 2016 7:00 AM UTC

Astellas said Japan approved an sNDA for a granule formulation of Kiklin bixalomer to treat hyperphosphatemia in patients on dialysis with chronic kidney disease (CKD). In 2012, Astellas launched a capsule formulation of the metal-free, non-absorbed polymeric phosphate-binding agent for the indication in the country. In February, Japan approved an sNDA for Kiklin capsules to treat CKD patients not on dialysis with hyperphosphatemia. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article